已收盤 11-20 16:00:00 美东时间
-0.521
-1.61%
Gain Therapeutics announced positive clinical data from a Phase 1b study of rexaceract for Parkinson's disease, showing stable MDS-UPDRS motor scores and no disease progression in 13 participants after 12 months of treatment. The study also highlighted the potential of cerebrospinal fluid (CSF) GluSph as a disease-specific biomarker, with differential responses observed between Parkinson's patients and one participant diagnosed with multiple syst...
11-17 21:15
Gain Therapeutics announced the presentation of two late-breaking posters at the 31st IAPRD World Congress on Parkinson’s Disease in Milan and one poster at Neuroscience 2026 in Washington, D.C. The posters highlight the company’s lead drug candidate, rexaceract (GT-02287), and its novel GCase allosteric modulator GT-04686, focusing on their potential in treating Parkinson’s disease and related disorders. The posters will be presented during guid...
11-05 12:00